Insight

The potential of precision medicine in gynaecologic cancers – ESMO

Photo from ESMO/LinkedIn

Jun 25, 2024, 03:43

The potential of precision medicine in gynaecologic cancers – ESMO

The European Society for Medical Oncology (ESMO) shared on LinkedIn:

“ESMOGynae24: The combination of comprehensive genomic profiling and ranking genomic alterations using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

After discussion in a Molecular Tumour Board, 22 patients received molecularly guided treatment options showcasing the potential of precision medicine in gynaecologic cancers, where ESMO is showing its commitment to facilitating patients’ access to optimal cancer care.”

Source: ESMO/LinkedIn

cancer ESCAT ESMO ESMO Scale for Clinical Actionability of molecular Targets ESMOGynae24 European Society for Medical Oncology gynaecologic cancers Molecular Tumour Board OncoDaily Oncology Precision Medicine

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage